Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Joshua F. Zeidner; Matthew C. Foster; Amanda L. Blackford; Mark R. Litzow; Lawrence E. Morris; Stephen A. Strickland; Jeffrey E. Lancet; Prithviraj Bose; M. Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D. Gocke; Gary L. Rosner; Richard F. Little; John J. Wright; L. Austin Doyle; B. Douglas Smith; Judith E. Karp

doi:10.1016/j.leukres.2018.08.005

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher D. Gocke, Gary L. Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith, Judith E. Karp

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Original language	English (US)
Pages (from-to)	92-95
Number of pages	4
Journal	Leukemia Research
Volume	72
DOIs	https://doi.org/10.1016/j.leukres.2018.08.005
State	Published - Sep 2018

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2018.08.005

Cite this

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C. D., Rosner, G. L., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D., & Karp, J. E. (2018). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia Research, 72, 92-95. https://doi.org/10.1016/j.leukres.2018.08.005

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). / Zeidner, Joshua F.; Foster, Matthew C.; Blackford, Amanda L. et al.

In: Leukemia Research, Vol. 72, 09.2018, p. 92-95.

Research output: Contribution to journal › Letter › peer-review

Zeidner, JF, Foster, MC, Blackford, AL, Litzow, MR, Morris, LE, Strickland, SA, Lancet, JE, Bose, P, Levy, MY, Tibes, R, Gojo, I, Gocke, CD, Rosner, GL, Little, RF, Wright, JJ, Doyle, LA, Smith, BD & Karp, JE 2018, 'Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)', Leukemia Research, vol. 72, pp. 92-95. https://doi.org/10.1016/j.leukres.2018.08.005

@article{cc37b2d77a22441299ebdd49efd80245,

title = "Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)",

author = "Zeidner, {Joshua F.} and Foster, {Matthew C.} and Blackford, {Amanda L.} and Litzow, {Mark R.} and Morris, {Lawrence E.} and Strickland, {Stephen A.} and Lancet, {Jeffrey E.} and Prithviraj Bose and Levy, {M. Yair} and Raoul Tibes and Ivana Gojo and Gocke, {Christopher D.} and Rosner, {Gary L.} and Little, {Richard F.} and Wright, {John J.} and Doyle, {L. Austin} and Smith, {B. Douglas} and Karp, {Judith E.}",

note = "Funding Information: This study was supported in part by NCI Cooperative Agreement U01 CA70095 and NCI Cancer Center Support Grant 2P30 CA06973-46. ",

year = "2018",

month = sep,

doi = "10.1016/j.leukres.2018.08.005",

language = "English (US)",

volume = "72",

pages = "92--95",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

AU - Zeidner, Joshua F.

AU - Foster, Matthew C.

AU - Blackford, Amanda L.

AU - Litzow, Mark R.

AU - Morris, Lawrence E.

AU - Strickland, Stephen A.

AU - Lancet, Jeffrey E.

AU - Bose, Prithviraj

AU - Levy, M. Yair

AU - Tibes, Raoul

AU - Gojo, Ivana

AU - Gocke, Christopher D.

AU - Rosner, Gary L.

AU - Little, Richard F.

AU - Wright, John J.

AU - Doyle, L. Austin

AU - Smith, B. Douglas

AU - Karp, Judith E.

N1 - Funding Information: This study was supported in part by NCI Cooperative Agreement U01 CA70095 and NCI Cancer Center Support Grant 2P30 CA06973-46.

PY - 2018/9

Y1 - 2018/9

UR - http://www.scopus.com/inward/record.url?scp=85051399141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051399141&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2018.08.005

DO - 10.1016/j.leukres.2018.08.005

M3 - Letter

C2 - 30118897

AN - SCOPUS:85051399141

VL - 72

SP - 92

EP - 95

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this